| Trial ID: | L2969 |
| Source ID: | NCT01253304
|
| Associated Drug: |
Ly2189265
|
| Title: |
A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01253304/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY2189265
|
| Outcome Measures: |
Primary: Pharmacokinetics: Maximum Observed Concentration (Cmax), This measure was calculated using non-compartmental analysis techniques., Predose to 336 hours postdose|Pharmacokinetics: Time of Maximum Concentration (Tmax), This measure was calculated using non-compartmental analysis techniques., Predose to 336 hours postdose|Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-tlast]), This measure was calculated using non-compartmental analysis techniques., Predose to 336 hours postdose|Pharmacokinetics: AUC From Time Zero to Infinity (AUC[0-infinity]), This measure was calculated using non-compartmental analysis techniques., Predose to 336 hours postdose|Pharmacokinetics: Apparent Terminal Elimination Half-life (t1/2), The half life associated with the terminal rate constant is summarized. This measure was calculated using non-compartmental analysis techniques., Predose to 336 hours postdose|Pharmacokinetics: Apparent Total Plasma Clearance (CL/F), The apparent total body clearance of drug calculated after extra vascular administration is summarized. This measure was calculated using non-compartmental analysis techniques., Predose to 336 hours postdose|Pharmacokinetics: Apparent Volume of Distribution (Vz/F), The apparent volume of distribution during the terminal phase after extra vascular administration is summarized. This measure was calculated using non-compartmental analysis techniques., Predose to 336 hours postdose |
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
26
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-11
|
| Completion Date: |
2011-11
|
| Results First Posted: |
2014-10-07
|
| Last Update Posted: |
2014-10-07
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, 81241, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, 1032, Hungary
|
| URL: |
https://clinicaltrials.gov/show/NCT01253304
|
